EGFR and prostate cancer: As a title of example, lapatinib is in a clinical trial for a number of solid tumors sharing the features of high EGFR and/or HER1/2 expression, particularly high-grade gliomas (NCT02101905), prostate cancer (NCT00246753), and head and neck cancers (NCT01044433).